Tianjin Tianyao Pharmaceuticals' high P/E ratio is alarming due to its three-year growth being lower than market predictions. If recent earnings trends persist, shareholders' investments could be at risk and potential investors may pay an excessive premium.
Despite a decrease in earnings per share, the company's stock continues to rise, suggesting expected future growth. Over the last five years, a 44% shareholder return, largely due to dividends, denotes positivity.
Tianjin Tianyao Pharmaceuticals Stock Forum
No comment yet